Vered Caplan - Orgenesis Insider

Orgenesis Inc -- USA Stock  

USD 6.8  0.4  6.25%

Chairman of the Board, Interim President and CEO

Ms. Vered Caplan serves as Chairman of the Board, Chief Executive Officer, President of the Company and Chief Executive Officer of Orgenesis Maryland Inc, a subsidiary of the Company. Vered Caplan was appointed President and CEO on August 14, 2014, prior to which she was Interim President and CEO since December 23, 2013. Since 2008, Ms. Caplan was Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for treatment of cancer. During the previous five years, Ms. Caplan was a director of the following companies Opticul Ltd., a company involved with optic based bacteria classification Inmotion Ltd., a company involved with selfpropelled disposable colonoscopies Nehora Photonics Ltd., a company involved with noninvasive blood monitoring Ocure Ltd., a company involved with wound management Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS and Biotech Investment Corporationration, a company involved with prostate cancer diagnostics
Age: 45  Chairman Since 2016      
Caplan has a M.Sc. in biomedical engineering from TelAviv University specializing in signal processing; management for engineers from TelAviv University specializing in business development; and a B.Sc. in mechanical engineering from the Technion specialized in software and cad systems.

Management Efficiency

The company has return on total asset (ROA) of (20.6) % which means that it has lost $20.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (114.75) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.01 M in liabilities with Debt to Equity (D/E) ratio of 71.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis Inc has Current Ratio of 0.31 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

Orgenesis Inc., a biopharmaceutical company, develops transdifferentiation technologies in the field of cell therapy and regenerative medicine. Orgenesis Inc (ORGS) is traded on OTC Market in USA. It is located in MARYLAND, U.S.A and employs 63 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Suggestion Now

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  NextLaunch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Orgenesis Inc to your portfolio

Top Management

Orgenesis Inc Leadership Team
David Sidransky, Director
Yaron Adler, Director
Marie Bouillez, Director
Neil Reithinger, CFO
Scott Carmer, CEO
Etti Hanochi, Director, MBA
Hugues Bultot, Director
Guy Yachin, Director, MBA
Chris Buyse, Director
Vered Caplan, Chairman
Sarah Ferber, Executive

Stock Performance

Orgenesis Performance Indicators